Name | Type | Description | Interventions |
---|
Arm 1_NSCLC | Experimental | Patients with solid non-small cell lung cancer (NSCLC) harboring NTRK fusions (arm closed) | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 2_Thyroid | Experimental | Patients with solid thyroid tumors harboring NTRK fusions (arm closed) | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 3_Sarcoma | Experimental | Patients with soft-tissue sarcoma harboring NTRK fusions (arm closed) | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 4_Colorectal | Experimental | Patients with solid colorectal tumors harboring NTRK fusions | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 5_Salivary | Experimental | Patients with solid salivary tumors harboring NTRK fusions (arm closed) | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 6_Biliary | Experimental | Patients with solid biliary tumors harboring NTRK fusions (arm closed) | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 7_Primary CNS | Experimental | Patients with solid tumors in the primary central nervous system (CNS) harboring NTRK fusions (arm closed) | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 8_Other tumors | Experimental | Patients with e.g. kidney cancer, squamous cell cancer of head or neck or ovarian solid tumors harboring NTRK fusions | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 9_Solid tumors without confirmed NTRK fusion | Experimental | Patients eligible for arms 1 to 8, but with documented NTRK fusion from a laboratory where CLIA or equivalent certification cannot be confirmed by the sponsor at the time of consent (arm closed) | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 10_Lung cancer | Experimental | Patients with lung cancer harboring NTRK fusions | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 11_Melanoma | Experimental | Patients with melanoma harboring NTRK fusions | - BAY2757556 (Larotrectinib, Vitrakvi)
|
Arm 12_Breast cancer | Experimental | Patient with non-secretory breast cancer harboring NTRK fusions | - BAY2757556 (Larotrectinib, Vitrakvi)
|